Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

17.3%

9 terminated/withdrawn out of 52 trials

Success Rate

65.4%

-21.2% vs industry average

Late-Stage Pipeline

8%

4 trials in Phase 3/4

Results Transparency

71%

12 of 17 completed trials have results

Key Signals

17 recruiting12 with results8 terminated

Enrollment Performance

Analytics

N/A
19(40.4%)
Phase 1
17(36.2%)
Phase 2
6(12.8%)
Phase 3
2(4.3%)
Phase 4
2(4.3%)
Early Phase 1
1(2.1%)
47Total
N/A(19)
Phase 1(17)
Phase 2(6)
Phase 3(2)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (52)

Showing 20 of 52 trials
NCT06185686Recruiting

Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients

Role: collaborator

NCT06340646Not ApplicableRecruiting

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Role: collaborator

NCT04420702Not ApplicableRecruiting

Diffusion Basis Spectrum Imaging of the Prostate

Role: collaborator

NCT07355205Phase 1Recruiting

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Role: collaborator

NCT04887935Phase 1Terminated

Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

Role: collaborator

NCT06310655Not ApplicableCompleted

Online Proton Adaptive Radiotherapy

Role: collaborator

NCT07379125Phase 1Recruiting

Therapeutic RSK1 Targeting in Myelofibrosis

Role: collaborator

NCT05944562Phase 1Active Not Recruiting

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

Role: collaborator

NCT07052305Phase 1Recruiting

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Role: collaborator

NCT04975139Active Not Recruiting

Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks

Role: collaborator

NCT04015700Phase 1Active Not Recruiting

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Role: collaborator

NCT06636162Early Phase 1Recruiting

Window of Opportunity Study of DSP-0390 in Gliomas

Role: collaborator

NCT04849871Not ApplicableActive Not Recruiting

Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma

Role: collaborator

NCT05111353Phase 1Completed

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery

Role: collaborator

NCT05743595Phase 1Active Not Recruiting

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Role: collaborator

NCT05187182Phase 1Recruiting

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Role: collaborator

NCT07126158Phase 2Recruiting

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Role: collaborator

NCT05837455Phase 2Recruiting

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Role: collaborator

NCT07283783Not ApplicableRecruiting

INCLUDE Program: A Perioperative Wellness Program Tailored for Black Surgical Patients

Role: collaborator

NCT06636149Not ApplicableRecruiting

Maternal Maneuvers During Prolonged Labor

Role: collaborator